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Abstract: An estimated 285 million people were living with diabetes 
in 2010, and this number is expected to reach 440 million by 2030. 
Current treatment of this disease involves the intradermal injection of 
insulin analogues. Many alternative administration routes have been 
proposed, the oral route being the most widely studied. One of the 
most interesting approaches for insulin delivery is the use of 
permeation enhancers to increase its transport across the 
gastrointestinal tract (GIT). Cell-penetrating peptides (CPPs) are a 
remarkable example of this family of compounds. Another alternative 
is the use of medium chain fatty acids (MCFAs) to temporally disrupt 
the tight junctions of the GIT, thereby allowing greater drug transport. 
A combination of both strategies can provide a synergistic way to 
increase drug transport through the GIT. 
Here we evaluated the complexation of insulin glulisine, an insulin 
analogue administered subcutaneously or intravenously in clinical 
practice, with a well-known CPP modified with the MCFA lauric acid. 
We have prepared several formulations, examined their stability, and 
tested the best candidates in an intestinal cell-based model. C12-r4 
and C12-r6 significantly increased the transport of insulin and thus 
emerge as a new delivery system worthy of further evaluation. 
 
Introduction 
Recent research in the fields of biomedicine and pharmacology 
have led to promising strategies to treat and cure several 
diseases. However, despite these huge breakthroughs, effective 
treatment for many others is still elusive. Although therapeutic 
agents achieve the desired purpose, they can cause long-term 
side effects. A clear example is the administration of insulin and 
its analogues, which provide the most convenient and effective 
treatments for diabetes mellitus but require multiple 
subcutaneous injections per day. This administration has multiple 
side effects, including pain, swelling and redness at the site of 
injection.[1] The development of other ways to administer insulin, 
such oral delivery, would provide a painless and friendlier delivery 
route for this protein.  
Peptides are now essential tools in pharmaceutical research 
owing to high specificity towards their targets, low immunogenic 
response, and relatively affordable price.[2] Among these 
molecules, peptide enhancers are widely used in biomedicine to 
improve the transport of therapeutic agents across biological 
barriers.[3] Regarding their mechanism of action, peptide 
enhancers are classified into three main groups. The first 
comprises transcellular enhancers, mostly CPPs (Figure 1.1) 
short peptides that interact with the plasma membrane, thus 
causing their cell uptake. Given their properties, transcellular 
enhancers can serve as a drug delivery system, increasing the 
absorption of the cargo into the desired tissue or cell type. The 
second group is formed by paracellular enhancers (Figure 1.2), 
which interact with tight junctions (TJs). These structures are 
closely associated areas between two cells responsible for cell-
cell adhesion and provide high impermeability towards 
substances. TJ modulators derive mainly from TJ proteins or 
toxins and include peptides with the ability to transiently open TJs. 
The third and final group comprises targeting peptides derived 
predominantly from phage display. These specific peptide 
enhancers direct the transport of a macromolecular agent into a 
specific tissue or cell type (Figure 1.3).  
Figure 1. Schematic representation of the intestinal membrane and the different 
transport mechanisms displayed by: 1. Transcellular peptide enhancers; 2. 
Paracellular enhancers (TJs modulators); 3. Targeting peptides.[4] 
 
A wide range CPPs have been described, including those derived 
from venoms[5] and viruses,[6] and synthetically designed peptides 
such as oligoarginines.[7] Many research groups have addressed 
their use to transport drugs across biological barriers. Examples 
include arginine-rich peptides like HIV-1 TAT peptide,[8] non-
natural oligoarginines such as D-octaarginine (r8),[9] and 
amphipathic peptides such as the Drosophila antennapedia 
homeodomain (penetratin), among others.[10] 
CPPs can be used in several ways to promote the absorption of 
therapeutic agents. They can be covalently conjugated or 
electrostatically bound[11] to the biotherapeutic,[8] or in 
combination with nanoformulations.[11] Many attempts with 
several CPPs have been made to deliver insulin into the 
bloodstream by crossing the gastrointestinal barrier as an 
alternative to the common subcutaneous administration method. 
One of the first studies in the field involved the use of a chemically 
synthesised TAT covalently bound to fluorescently labelled insulin 
(insulin-FITC).[8] The use of TAT/insulin-FITC caused a 6- to 8-
fold increase in insulin transport across a Caco-2 cell monolayer 
(the gold-standard cellular model to simulate the epithelial cell 
layer) compared to insulin-FITC alone. A few years later, 
Morishita et al. tested the capacity of 10 distinct CPPs 
electrostatically bound to insulin to enhance cell membrane 
permeation. In this regard, L-Penetratin and L-pVec, followed by 
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D-octaarginine (r8), showed the best performance with regard to 
increasing insulin bioavailability and low toxic effects.[12] In 
another study, r8 was co-administered as a physical mixture 
(electrostatically bound) with various peptide drugs.[9] They found 
that the peptide drugs with higher transport through in situ ileum 
loop were those with negative charges. Peptide drugs with a 
neutral charge or positive charged were not able to cross the 
ileum membrane. These results demonstrated that the binding 
affinity (electrostatic) between drugs and CPPs is crucial for drug 
absorption in the intestine. Moreover, the binding ratio between 
insulin and r8 was a key factor as an increase in the ratio of CPP 
bound led to enhanced intestinal absorption of insulin. 
Here we examined peptides, in particular CPPs, as penetration 
enhancers. The selected CPPs were modified with a certain 
MCFA, reported as a penetration enhancer.[13] The unmodified 
CPP were not included in this work since they have been already 
widely studied.[14] Fatty acid-based compounds are a great source 
of absorption enhancers. Despite the potential of these 
compounds, some concerns have been raised regarding their 
toxicity.[15] Sodium caprate (C10) in particular has been extensively 
studied for in vitro and in vivo studies.[16] This MCFA, as well as 
its homologues (C8, C12, C14, C16, etc), cause cytotoxicity in a 
concentration- and time-dependent manner. In spite of this, 
several reports have studied the safe concentration range in 
which these compounds can be used as permeation enhancers 
in vitro[17] More importantly, fine control of the concentration used 
has allowed the use of C10 in clinical trials.[18] Therefore, 
modulation of the dose of MCFAs can enhance the intestinal 
absorption of biotherapeutics without causing remarkable 
cytotoxicity. In addition, the combined effect of TJ modulator 
peptides and MCFAs had a greater effect on paracellular 
transport, where C14 covalently bound to the TJ modulator peptide 
protected it from degradation and aggregation.[19] In 2015, Zhang 
et al. reported a synergistic effect when using amphiphilic 
lipopeptide-insulin complexes compared to r8 alone.[20] In that 
case, the use of stearic acid and incorporation of glutamic acid 
and tryptophan increased the stability of the complex and, 
therefore, the transport of insulin. 
Although lipopeptides have the potential to increase insulin 
bioavailability through the intestinal tract, they have several 
drawbacks. One of the main problems is the low peptide stability 
in the gastrointestinal environment, which makes them 
susceptible to enzymatic degradation.[21] Furthermore, it has been 
observed that the complexes formed between CPPs and insulin 
show instability across the intestinal tract, possibly because of the 
high ionic strength in the intestinal media. In addition, at a certain 
molar ratio, insoluble aggregates are observed.[12] In this regard, 
many strategies, such as the use of polymer coatings,[22] have 
been tested to preserve the stability of these complexes during 
intestinal absorption. 
In this article, four distinct lipopeptides (Figure 2) were used to 
form complexes with insulin glulisine (commercially known as 
Apidra®). Glulisine is a new generation insulin analogue 
characterised by its rapid onset of action. 
We hypothesised that self-aggregation occurs as a result of the 
amphipathic nature of lipopeptides, which would lead to micelle 
formation. Lipopeptide micellization may affect the structure of 









Figure 2. Sequences of the four lipopeptides used: C12-r4 (n=1), C12-r6 (n=2), 
C12-r8 (n=3), C12-r12 (n=5). 
 
In this regard, the critical micelle concentration (CMC) of our 
lipopeptides was determined by isothermal titration calorimetry 
(ITC). In addition, the hydrodynamic properties of the complexes, 
such as size and -potential, were measured by dynamic light 
scattering (DLS) in order to better understand their behaviour in 
response to variations in the pH, ionic strength or composition of 
the medium. Moreover, we screened various molar ratios of the 
four lipopeptides and glulisine in order to optimize the binding 
efficiency and stability of the complexes. Finally, the optimised 
complexes were assayed in the Caco-2/HT-29 transport model, 
and the amount of glulisine transported across the cells was 
determined using various analytical techniques. 
 
Results and Discussion 
1. Determination of critical micelle concentration 
 
Lipopeptide aggregation behaviour in solution is a crucial factor to 
study with respect to stability of the lipopeptide-glulisine complex. 
Weak complex stability caused by lipopeptide self-aggregation 
could lead to reduced glulisine transport across the intestinal 
barrier. We therefore explored whether the formation of micelles 
triggers complex aggregation. 
ITC is a calorimetric high-precision technique that can be used to 
determine thermodynamic parametes associated to micelle 
formation.[23] In our case titration experiments of each lipopeptide 
into HBSS were performed to obtain the CMC (Supporting 
information, Figure S1). As an example, various interactions were 
observed in the lipopeptide C12-r6 (Figure S1B): peaks 1 to 14 
showed thermal effects produced by exothermic interactions, 
while peaks 15 from 24 showed the process derived from 
endothermic interactions. The concentration obtained from the 
transition of peak 14 to 15 corresponds to the CMC. Corrected 
heat, in kJ/mol, correspond to each injection of lipopeptides into 
HBSS, and the heat rate is represented inversely (Figure S2). 
CMC and other thermodynamic parameters were calculated for 
all the lipopeptides.[24]  
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Table 1. Critical Micelle Concentrations (mM) and ΔH micellization (kJmol-1) 
corresponding to each lipopeptide at 37ºC with HBSS as solvent. Data are 
expressed as mean ± SD, n =2. 
CPP Temp/ºC Solvent CMC/mM ΔHmic /kJmol-1 
C12-r12 37 HBSS 4.56 ± 0.46 2.16 ± 0.73 
C12-r8 37 HBSS 2.04  ± 0.78 7.66 ± 4.19 
C12-r6 37 HBSS 4.07 ± 0.86 1.24 ± 2.69 
C12-r4 37 HBSS 0.67 ± 0.25 0.50 ± 0.72 
 
All the CMCs determined were above the maximum concentration 
used to form the complexes (0.48 mM was the maximum 
concentration used for C12-r4). With these results, the hypothesis 
that concentrations above the CMC would trigger complex 
precipitation was discarded. Thus, lipopeptides were in their non-
micellar form and electrostatic interactions with glulisine were not 
altered by micellation processes.  
Bile salts act as a surfactant, emulsifying dietary fats into micelles 
and thus facilitating their digestion. As the lipopeptide structure 
contains a fatty acid chain, the bile salts may cause early 
micellization. To study variations in the lipopeptide CMCs caused 
by pH variation or the presence of bile salts, we prepared a fasted 
simulated intestinal medium (FaSSIF). Again, ITC was performed 
to study C12-r4 in FaSSIF medium at the same concentration 
studied previously in HBSS (Figure S3). Our results showed that 
all the titrations were exothermic and, in contrast to what was 
expected, the CMC was not reached in this case. Therefore, we 
assumed that an increase in CMC for all the lipopeptides would 
be observed in FaSSIF. The interaction of the lipopeptides with 
the bile salts of the media could explain this phenomenon.  
 
2 Evaluation of the formulation of physicochemical properties 
 
We studied the effect of factors such as the preparation of 
glulisine stock solution, molar ratio between the lipopeptide and 
glulisine and ionic strength of the buffer on complex size, charge 
and tendency to aggregate.  
 
2.1 Procedure to dissolve glulisine  
 
A well reported procedure to solubilise insulin for the formation of 
complexes with positively charged peptides is the addition of HCl 
(0.1M), followed by the addition of the desired buffer, and finally 
pH adjustment with NaOH (0.1M).[9, 20] Insulin and peptides are 
then mixed to form the complexes at a specific molar ratio. 
In our hands, this methodology resulted in highly polydisperse 
samples regarding particle size (measured by DLS), thereby 
indicating that glulisine was not well dissolved and aggregation 
was taking place. The same results were obtained when insulin 
was first dissolved with NaOH (0.1M), followed by pH adjustment 
with HCl (0.1M). 
We found that the most efficient approach to solubilise glulisine 
was with a NaOH solution (0.01M). The complexes with the 
lipopeptide were then formed. Next, the desired buffer was added 
and the pH was adjusted. 
In addition, the pH achieved when dissolving glulisine in NaOH 
0.01M conferred the complexes extra negative charges, thus 
increasing electrostatic interaction efficiency with the positively 
charged lipopeptides and resulting in samples with greater 
monodispersity.  
 
2.2 Lipopeptide:glulisine molar ratio 
 
Particle size and -potential were measured after preparing the 
formulations. The effect of a range of molar ratios between 
lipopeptides and glulisine was tested on these two parameters. 
Lipopeptide concentration ranged from 15 µM to 480 µM while 
glulisine concentration remained constant at 15 µM. The results 
are given in the Supporting information (Table S1). On the one 
hand, for both C12-r12 and C12-r8, a molar ratio higher than 4:1 
resulted in nanometric particles with an average size of 200 nm 
(Figure 3A and 3B, respectively). However, molar ratio of 1:1 
resulted in aggregation and, consequently, particle size exceeded 
2 µm in both cases. On the other hand, C12-r6 and C12-r4 showed 
a different tendency. For complexes formed by C12-r6:glulisine, 
molar ratios ranging from 8:1 to 1:1 resulted in particle 
aggregation (Figure 3C). Nevertheless, molar ratios of 16:1 and 
12:1 resulted in nanometric particles. In the case of C12-r4, 
completely different behaviour was observed, as molar ratios of 
1:1 and 32:1 resulted in particles with a diameter slightly over 200 
nm (Figure 3D). However, molar ratios ranging from 4:1 to 16:1 
yielded particle aggregation. 
The-potential of the nanocomplexes is another parameter 
indicating particle aggregation. Lipopeptides containing a greater 
number of arginine residues in their sequence (C12-r12 and C12-
r8) yielded higher -potential values at lower molar ratios 
compared with C12-r6 and C12-r4.Thus, at molar ratios of 4:1 and 
8:1, C12-r12 and C12-r8 formed complexes with enough positive 
surface charge to be stable (Figure 3A and 3B). Nevertheless, in 
both cases, a molar ratio of 1:1 gave a lower -potential and, as a 
result, larger particle size. 
-potential is a key indicator of particle stability.[25] In many cases, 
values close to zero indicate poor stability as a result of weak 
repulsion between charges. 
This concept is reflected in Figure 3D, where an almost zero -
potential (between +10 and -10 mV) correlates with particle 
aggregation. Otherwise, values higher than ±10 mV, such those 
corresponding to molar ratios of 32:1 and 1:1 for C12-r4 resulted 
in nanometric complexes. Only one exception was observed for 
C12-r12 at molar ratio of 1:1. In this case, aggregation takes place 
at high -potential. Several studies outline the importance of the 
CPP concentration for the insulin association efficiency.[9, 12] Thus 
at low concentrations, such as the one corresponding to 1:1, C12-
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Figure 3. Measurement of particle size and -potential: (A) C12-r12, (B) C12-r8, (C) C12-r6 and (D) C12-r4. Data expressed as mean + SD for Particle size, and mean 
± SD for -Potential, n= 6-18.
 
2.3 Ionic Strength 
 
Given that ionic strength plays a key role in the colloidal stability of 
electrostatic formulations, we studied the physicochemical properties 
of complexes in a range of buffer solutions, analysing both particle 
size and -potential.  
First, HBBS was selected since it is the most commonly used buffer 
for in vitro intestinal models. Results showed that the high amount of 
salts have a strong effect on the size of the complexes (Figure 4A).  
For the complexes formed with C12-r12 and C12-r8, the increase in the 
ionic strength led to aggregation, thereby modifying particle size from 
around 200 nm to more than 1000 nm at molar ratios (CPP:glulisine) 
of 8:1 (Figure 4A) and 4:1 (Table S1). 
In the case of C12-r6 and C12-r4, there was also an increase in the 
particle size but it was less than that observed for the previous 
complexes (Figure 4A). In all cases, the particle size increased when 
HBSS buffer was used, compared with complexes formed in aqueous 
solution. 
Regarding the -potential, lower values were registered in all the 
complexes assayed (Figure 4B and Table S1), except for the molar 
ratio 1:1 of C12-r4, which led to an increase in this parameter (Table 
S1). 
The high ionic strength of the buffer has been reported to affect 
electrostatic and hydrophobic interactions.[26] Therefore, we 
hypothesised that HBSS decreases the repulsive electrostatic 
lipopeptide-glulisine interactions. There is a strong correlation 
between protein solubility and protein-protein interactions. In this 
regard, a decrease in electrostatic repulsion results in a decrease in 
protein solubility.[27] Complexes present positive charges (conferred 
by arginine residues) and negative charges (glulisine), while HBSS 
contains both cations and anions in solution. 
Consequently, these ions interact with both lipopeptides and glulisine, 
thus hindering the formation of the complex, as reflected by an 
increase in their size. 
 
As previously mentioned, -potential is used as a parameter to 
measure particle stability in solution. The decreases in -potential 
brought about by the salts are the main cause of complex 
aggregation owing to weak positive-positive repulsion between 
surface charges. However, even with this decrease in -potential and 
the evident aggregation, no visible precipitation of the complexes was 
observed after 2 h in HBSS. In summary, the selection of an optimal 
ionic strength is a difficult issue that must be addressed by achieving 
an equilibrium between the deleterious effect of high ionic strength 
on particle size and -potential and the minimal salt content required 
to ensure cell survival during transport assays. Although the use of 
polymers to protect the complexes could be useful, this approach 
would introduce other drawbacks, such as potential polymer toxicity 
or long degradation times. 
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Figure 4. Effect of ionic strength on A) particle size and B) -potential. Data are 
expressed as mean + SD n= 6-18. Symbol meaning: ns (P > 0.05), * (P≤ 0.05), ** 
(P ≤0.01), *** (P≤0.001), and **** (P≤0.00001). 
 
3. Caco-2/HT-29 transport assay 
 
Caco-2 cells are the gold-standard to simulate the intestinal barrier 
as they recapitulate the morphological and functional characteristics 
of mature enterocytes.[28] Their ability to form a monolayer and 
express TJs are crucial properties that make them ideal as a model 
to study glulisine transport across the intestinal epithelium. In addition, 
these cells express microvilli, enzymes and transporters that are 
unique to enterocytes. However, they present some limitations, such 
as the lack of mucus secretion. Therefore, in order to work with a 
more realistic intestinal environment, we used co-cultures with 
mucus-secreting HT-29 cells.[29]  
The optimised formulations of the amphiphilic lipopeptides and 
glulisine were assayed in this cellular model as drug delivery system 
across the Caco-2/HT-29 cell monolayer.  
 
Transepithelial electrical resistance (TEER) is a quality indicator of 
cell monolayer integrity as it measures the electrical resistance that 
this monolayer offers against electrical current.[30] In transport studies, 
TEER values were measured at 0, 2 and 24 h in order to monitor 
membrane disruption. 
Various profiles were observed when the complexes were assayed 
in the Caco-2/HT-29 model (Figure S4). Glulisine did not affect TEER 
as it remained stable throughout the 24-h experiment. However, the 
complexes formed with the four lipopeptides had different effects on 
the Caco-2/HT-29 cell monolayer. After 2 h, complexes formed with 
C12-r12, decreased TEER from 100% to 53% and 42% for molar ratios 
of 4:1 and 8:1, respectively (Figure S4A). At 24 h, TEER was reduced 
to 32% and 30% for molar ratios of 4:1 and 8:1. The lipopeptide C12-
r8 showed similar results for the two molar ratios assayed: TEER was 
reduced from 100% to 97% in 2 h and decreased to 67% in 24 h at a 
molar ratio of 4:1. When the molar ratio was 8:1, TEER also 
decreased, from 100% to 74% in 2 h and to 49% in 24h.  
A completely different scenario was observed for C12-r6. In this case, 
TEER decreased after 2 h at the higher molar ratios tested (Figure 
S4B); however, none of the values fell below 75%. At 24 h, only the 
molar ratio of 4:1 maintained TEER around 100%, the rest of the 
formulations maintained the decreased TEER constant. 
Two distinct profiles were observed when the complexes were 
formed with C12-r4 (Figure S4C): molar ratios corresponding to 32:1 
and 1:1 registered a notable reduction in TEER after 2 h, followed by 
a recovery of this parameter at 24 h, while molar ratios of 8:1 and 4:1 
showed a gradual increase of TEER up to 110% and 120%, 
respectively, over the 24-h experiment.  
Analysis of the TEER measurements in the Caco-2/HT-29 transport 
assay revealed that the complexes formed with longer oligoarginine 
(C12-r12 and C12-r8) had a more pronounced effect on the cell 
monolayer resistance compared with the others. This finding was 
reflected in a decrease in TEER, with no apparent recovery at 24 h, 
thus indicating cell monolayer disruption. In contrast, the effect of C12-
r6 and C12-r4 on the cell monolayer was not as harmful as that of the 
richer arginine peptides. This observation was reflected in a reduction 
in TEER, which was not below 75% in any case and was recovered 
or maintained in most of the cases. 
Comparing the same lipopeptide but different molar ratios, in all 
cases TEER decreased when the molar ratio increased. This effect 
can be attributed to the higher number of MCFAs present in the 
complex. 
To quantify glulisine transport, the samples from the acceptor 
compartment were collected and analysed by UPLC-MS. The 
molecular weight of glulisine was detected in C12-r6:glulisine (4:1) and 
C12-r4:glulisine (1:1) but no quantitative results were obtained. 
We then lyophilised the samples and concentrate them 10 fold. After 
resuspension, samples were analysed by UPLC and transported 
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This cellular model allowed us to identify two formulations that can 
improve the transport of glulisine through the intestinal barrier.  
C12-r6 at a molar ratio of 4:1 and C12-r4 at a molar ratio of 1:1 
significantly increased glulisine transport across the Caco-2/HT-29 
monolayer. In the case of the C12-r12 and C12-r8 formulations (Figure 
5 A), the amount of glulisine detected was similar to the control. In 
contrast, for C12-r6 formulations (Figure 5 B), a slight increase in 
glulisine transport was observed in all the conditions assayed except 
for the molar ratio of 12:1. Remarkably, the molar ratio of 4:1 
increased the transport of glulisine by 30%. Similar results were 
observed for C12-r4 formulations (Figure 5 C). A slight increase in 
glulisine transport was detected for molar ratios of 32:1 and 4:1. 
However, the 1:1 molar ratio significantly increased glulisine transport 
up to 40%. These results highlight the potential of these formulations. 
Although the use of Caco-2/HT-29 monolayers to evaluate intestinal 
permeability is widely used,[31] direct correlation with in vivo transport 
cannot be done. The information extracted from this model should be 
considered only as qualitative indication of transport.[32] 
These results reveal that the transport of glulisine through the Caco-
2/HT-29 monolayer is inversely proportional to the number of arginine 
residues in the lipopeptides used in the formulations. Furthermore, in 
our hands, as the molar ratio increased, glulisine transport decreased.  
A recent study highlighted the importance of negative and neutral 
surface charge particles for diffusivity through porcine intestinal 
mucus.[33] On the basis of finding on negative mucus glycoproteins 
such as the mucin[34] secreted by HT-29 cells,[35] electrostatic binding 
between mucin and complexes could be the plausible cause of the 
poor transport of the more polar positively charged formulations 
(those containing C12-r12 and C12-r8). In contrast, neutral and 
negative formulations such those corresponding to C12-r6 and C12-r4 
would be electrostatically trapped to a lesser extent in the mucus and 
could promote the transport of glulisine across the cell monolayer 
more efficiently. If we consider the particle size of these complexes, 
C12-r6: glulisine 3715 nm, C12-r4: glulisine 992 nm, a disaggregation 
process that results in size reduction upon interaction with mucus can 
be proposed. These phenomena has to be further evaluated. 





Figure 5. Representation of the relative transport of glulisine across the Caco-2/HT-29 model compared with glulisine alone. A) C12-r12 and C12-r8 formulations, B) 




Here we studied complexes formed by amphiphilic lipopeptides 
and glulisine as potential permeation enhancers. Several 
parameters were examined and optimised. As general trend, the 
size and homogeneity of the complexes were strongly affected by 
changes in pH, molar ratio and ionic strength. These changes can 
be caused by the self-assembly of the lipopeptides which can 
occur at concentrations below the CMC due to their amphipathic 
character. Two of the formulations tested, namely positively 
charged C12-r6 at a molar ratio of 4:1 and negatively charged C12-
r4 at a molar ratio of 1:1, enhanced the passage of glulisine 
through the Caco-2/HT-29 model approximately a 30 and 40%, 





Lipopeptides were synthesised by Solid-phase Peptide Synthesis (SPPS) 
following the Fmoc/t-Bu strategy. H-Rink Amide-ChemMatrix® resin was 
used to obtain C-terminal amidation. Peptide elongation was performed 
manually using PyAOP and DIEA as coupling reagents. After the 
introduction of each amino acid, the Kaiser test[36] was used to ensure high 
coupling efficiency. Fmoc deprotection was performed by the addition of 
20% piperidine in DMF. Lauric acid was coupled to the N-terminus using 
the previous strategy. The peptides were deprotected and cleaved from 
the resin using the following mixture: TFA:TIS:H2O (95:2.5:2.5) for 4-5h. 
Peptides were purified by RP-HPLC at semi-preparative scale (Sunfire C18 
column (150 x 10 mm x 5 μm, 100 Å, Waters), flow rate 6.6 mL/min using 
Acetonitrile (0.1% TFA) and H2O (0.1% TFA) and characterised by UPLC 
and UPLC-MS (Acquity UPLC® BEH C18 column (50 x 2.1 mm x 1.7 μm, 
Waters) coupled to a PDA Acquity detector and SQ detector 2, flow rate 
0.6 mL/min using Acetonitrile (0.036% TFA) and H2O (0.045% TFA)). All 
peptides were obtained with high purity (> 95%) and stored lyophilised at 
-20ºC. 
Determination of critical micelle concentration  
Titration experiments were performed in a Low-Volume Nano ITC (TA 
Instruments). The sample cell was filled with the buffer. The syringe 
contained a concentrated solution of the desired lipopeptide in HBSS. 
Each titration experiment consisted of 24 injections of 2 μL of each 
lipopeptide into a sample cell (280-sec interval) with a stirring speed of 
207rpm. A first injection of 0.5 μL was performed to avoid air bubbles. 
Sample cell and syringe samples were degassed for 15 min and 
centrifuged for 15 sec at 6,000 rpm before each titration experiment. 
Fasted simulated intestinal fluid (FaSSIF) was also used to simulate the 
effect of bile salts.[37] The experimental data were analysed by TA  
Instruments NanoAnalyzeTM software. CMCs and other thermodynamic 
parameters were calculated by a Microsoft Excel macro kindly provided by 
Prof. Dr. Sandro Keller.[24]  
Complexes preparation 
500 µL of glulisine (in 0.01M NaOH) solution was placed in a glass vial, 
and the same volume of lipopeptide aqueous solution was added while the 
solution was under magnetic stirring. After 10 min, pH was adjusted to 7.4 
with HCl 0.1M. For Caco-2/HT-29 transport assay, lipopeptides and 
glulisine were mixed as previously explained. Concentrated HBSS was 
then added in order to obtain the desired lipopeptide:glulisine molar ratio 
in a standard HBSS solution. 
Dynamic light scattering  
The particle size and -potential of all the formulations were determined by 
DLS using a Malvern Zeta-Sizer (NanoZS, ZEN 3600, Malvern 
Instruments) upgraded with -potential capability. The equipment was 
adjusted to 3 measures of 3 runs (10 sec per run) for size measurements 
and 3 measures of 10 runs for -potential. The temperature was set at 
25ºC and the scattering angle to 173º. Data analysis was performed using 
Zeta-Sizer software. 
Cellular transport model 
For the transport model, co-cultures of Caco-2 and HT-29 cells were 
prepared. Passages from 7 to 11 were used in both lines. The insert (PET, 
1µm pore size, Falcon) was prepared as follows:  
300 µL of cold Corning® Matrigel® (10 uL/mL in non-supplemented DMEM) 
was incubated in each insert, in sterile conditions, for 1 h. Matrigel was 
then removed, and inserts were washed three times with non-
supplemented DMEM medium. Caco-2 (90%) and HT-29 (10%) cells were 
added to each insert (300,000 cells per well) in 500 µL of complete DMEM 
medium. Next, 1.5 mL of complete DMEM was added to the donor 
chamber of each well to each well in the donor side, and cells were grown 
at 37ºC and 5% CO2 for 21 days in order to obtain a cell monolayer. 
Medium was replaced every other day. TEER was measured as a control 
of monolayer formation. Medium was changed every two days.  
For transport studies, the acceptor (0.5mL) and donor (1.5 mL) chambers 
were equilibrated with HBSS buffer for 30 min at 37ºC and 5% CO2. After 
this time, the lipopeptide complexes were incubated for 2 h in the acceptor 
chamber at 37ºC and 5% CO2. To evaluate the effect of the different 
formulations on the cell monolayer, TEER was measured before sample 
addition and 2 h and 24 h after sample addition. 
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Glulisine quantification 
 
Time0, Donor and Acceptor samples were concentrated 10-fold and 
analyed by UPLC-MS. The gradient used was from 15% to 65 % Acetonitril 
in 2 min. Glulisine retention time was 1.39 min. A calibration curve of 
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Intestinal permeation enhancers: We report various D-polyarginines 
modified with a lipid moiety in order to increase the transport of insulin 
through a CaCo-2 cell model. Stability of the complexes were deeply 
studied and the best candidates were assayed in the cellular model. These 
new systems emerge as a new delivery system. 
 
